---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-100115"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:09:33.520155+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quoin grants exclusive license for QRX003 in Singapore to Farma Mondo

## Summary
- Exclusive license to Farma Mondo SA to commercialize QRX003 in Singapore.
- Licensee must file for regulatory approvals within 6 months of Quoin's FDA/EMA approval.
- Financial terms not disclosed; royalties payable to Quoin.
- Parties to negotiate supply agreement for product manufacture and supply.

## SEC filing metadata
- accession: 0001104659-23-100115
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/0001104659-23-100115-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/tm2325985d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-100115
- JSON: https://secwatch.observer/filing/0001104659-23-100115.json
- Plain text: https://secwatch.observer/filing/0001104659-23-100115.txt

## Key facts
- Material Agreements
  Quoin Pharmaceuticals, Ltd. entered into Exclusive License and Distribution Agreement with Farma Mondo SA valued at Exclusive license to commercialize QRX003 in Singapore, royalty-bearing (effective 2023-09-01).
  - Action: entry
  - Agreement: license
  - Counterparty: Farma Mondo SA
  - Value: Exclusive license to commercialize QRX003 in Singapore, royalty-bearing
  - Effective: 2023-09-01
  source text: On September 6, 2023, Quoin Pharmaceuticals Ltd. (the “Company”) entered into an Exclusive License and Distribution Agreement, effective as of September 1, 2023 (the “License Agreement”), with Farma Mondo SA, a company incorporated under the laws of Switzerland (“Farma Mondo”). Pursuant to the License Agreement, the Company granted to Farma Mondo an exclusive license under its Product Technology (as defined in the License Agreement) to commercialize, upon receipt of applicable regulatory approvals, pharmaceutical product QRX003 (in finished dosage form for human use) in Singapore.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923100115/0001104659-23-100115-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.